AGGRESSIVE NHL

Poster number

Title

Submitting author

City and Country

166

High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS –From the REMARC study

Catherine Thieblemont

Paris, France

167

LYMFOREST-25: PERSONALLY-TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA USING CLINICO-GENOMIC PROGNOSTIC MODELS

Adrián Mosquera Orgueira

Santiago De Compostela, Spain

168

Prognostic significance of time from last therapy in patients with diffuse large B-cell lymphoma: retrospective analysis of electronic health records and claims data in the US

Matthew Matasar

New York, NY, USA

169

A single blood test is able to classify DLBCL patients in three prognostic clusters at diagnosis

Fernando Martín Moro

Madrid, Spain

170

Finding a concordant or discordant bone marrow involvement by histology or flow cytometry at DLBCL NOS diagnosis implies a worse prognosis whereas PET-FDG does not

Fernando Martín Moro

Madrid, Spain

171

Interim PET/CT predicts outcomes of Diffuse Large B-cell Lymphoma (DLBCL) treated with frontline lenalidomide/RCHOP (R2CHOP): long-term analysis of MC078E.

Sanjal Desai

Rochester, MN, USA

172

Bone marrow infiltration assessment by FDG18-PET: can this imaging test replace bone marrow trephine biopsy in Diffuse Large B cell lymphoma staging?

Sara Duarte

Coimbra, Portugal

173

The elderly prognostic index (EPI) predicts early mortality in older patients with DLBCL. A substudy of the Elderly Project by the Fondazione Italiana Linfomi (FIL).

Francesco Merli

Reggio Emilia, Italy

174

Polatuzumab vedotin with bendamustine and rituximab for relapsed/refractory high-grade B-cell lymphoma: The UK Experience

Michael Northend

London, UK

175

Bendamustine, rituximab, and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma: Single-center real-world experience

Kyle Farina

New York, NY, USA

176

Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary results of the SELINDA phase Ib LYSA Study ( EUDRACT Number: 2015-005612-15)

Marie Maerevoet

Brussels, Belgium

177

LOTIS 2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma

Pier Luigi Zinzani

Bologna, Italy

178

Estimation of long-term survival with tafasitamab + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

Dan Huang

Planegg, Germany

179

Central nervous system relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP: Study of the Spanish Lymphoma Group GELTAMO

Mireia Franch-Sarto

Badalona, Spain

180

A Single-center Retrospective Analysis of the Toxicity of High-dose Methotrexate (HDMTX) Administered on the First Day of (R)CHOP in Aggressive nonHodgkin Lymphomas (aNHLs)

Yazeed Sawalha

Columbus, OH, USA

181

SAFETY AND EFFICACY OF THE “CARMEN” REGIMEN, A NEW DOSE-DENSE SHORT-TERM THERAPY IN PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA AND MYC REARRANGEMENT

Andrés Ferreri

Milan, Italy

182

Updated results of a phase 2 study from GELTAMO investigating the combination of ibrutinib with R-GEMOX in patients with relapsed or refractory diffuse large B-cell lymphoma

Beatriz Rey Búa

Salamanca, Spain

183

Diffuse Large B Cell Lymphoma (DLBCL) in late-octogenarian (LO) patients: a substudy of the “Elderly Project” by the Fondazione Italiana Linfomi (FIL)

Alessandra Tucci

Brescia, Italy

184

LONG-TERM OUTCOMES OF ELDERLY PATIENTS TREATED WITH FRONTLINE R-CHOP: UPDATE OF THE LNH03-6B TRIAL

Vincent Camus

Rouen, France

185

Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Aung Tun

Westwood, KS, USA

186

Impact of Time to Relapse and Response to Salvage Therapy on Post Autologous Stem Cell Transplant Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Aung Tun

Westwood, KS, USA

187

Autologous transplant in elderly patients with R/R aggressive lymphoma selected by simplified CGA: the RECANZ prospective phase 2 study by the Fondazione Italiana Linfomi

Alessandra Tucci

Brescia, Italy

188

Allogeneic hematopoietic stem cells transplantation for Non-Hodgkin’s lymphoma in Switzerland. 35 years of experience 1985-2020. For SBST working group.

Ekaterina Rebmann Chigrinova

Bern, Switzerland